RecruitingPhase 4NCT06843044
Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders
Valenta Pharm JSCn = 25013 Jan 2025 to est. 31 Dec 2027
Anxiety · Neurasthenia · Adjustment Disorders
GB-115 / Studies
Synthetic analog · 2 amino acids · 434.5 Da
GB-115 studies and research data
PepBank has 21 GB-115 studies with results. All of them gave GB-115, with 91 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 91 results and 25 papers. Newer studies from Europe PMC
Results in people
24
26% of 91 results
Results in animals
67
74% of 91 results
Results in lab cells
0
0% of 91 results
From computer models
0
0% of 91 results
The molecule
GB-115 identity
Identifiers, parent molecule, targets and development stage, from curated data.
GB-115 is N-(6-phenylhexanoyl)-glycyl-L-tryptophanamide, a synthetic retrodipeptide analog of cholecystokinin-4. Recent clinical reports describe CCK1 antagonism, while older animal studies describe CCK2 antagonism. These sources do not resolve receptor subtype selectivity. Valenta markets the product in Russia as Ranquilon.
- Kind
- Synthetic analog · 2 residues
- Identifiers
- PubChem CID11281948 (opens in a new tab)UNIIG5YT2F7SG8 (opens in a new tab)CAS678996-63-9
- Parent
- Analog of Cholecystokinin-4 (CCK-4)The primary synthesis study describes GB-115 as a CCK-4 dipeptide analog. This mimetic relationship does not establish a contiguous parent sequence range.
- Development
- Approved in Russia onlyZakusov Institute of Pharmacology (originator), Valenta Pharm JSC (clinical sponsor and marketer)Valenta reports Russian medicinal registration. ClinicalTrials.gov records completed phase III NCT05586789 and recruiting phase IV NCT06843044. Phase IV enrollment remains estimated. Registry and publication updates can differ. Source (opens in a new tab)
Targets
| Target | Action | Evidence |
|---|---|---|
| CCKARCCKARP32238 (opens in a new tab) | Antagonist | Clinical pilot report describes CCK1 antagonism.Source (opens in a new tab) |
| CCKBRCCKBRP32239 (opens in a new tab) | Antagonist | Animal pharmacology report proposes CCK2 antagonism.Source (opens in a new tab) |
Sequence and structure
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
Sequence
2 amino acids · 2 modifications
Residues 1 to 2:
W
Parent: Cholecystokinin-4 (CCK-4)
No sequence is listed for the parent, so no alignment is shown.The primary synthesis study describes GB-115 as a CCK-4 dipeptide analog. This mimetic relationship does not establish a contiguous parent sequence range.
Properties
From identity sources
- Formula
- C25H30N4O3
- Molecular weight
- 434.5 g/mol
- Monoisotopic mass
- 434.2318 Da
- PubChem CID 11281948(opens in a new tab)retrieved 2026-10-27
- FDA GSRS G5YT2F7SG8(opens in a new tab)retrieved 2026-10-27
- primary synthesis 17886432(opens in a new tab)retrieved 2026-10-27
Calculated from the sequence
Some values cannot be calculated. A modification changes this value and is not modeled here (for example a lipid, metal or linker).
- Average mass
- Not calculated
- Monoisotopic mass
- Not calculated
- Isoelectric point (pI)
- Not calculated
- Net charge at pH 7.4
- Not calculated
- GRAVY (hydropathy)
- −0.650
- Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982
- Negative: hydrophilic on average.
- Extinction coefficient, 280 nm (Cys reduced)
- 5,500 M⁻¹ cm⁻¹
- 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam)
- Instability index
- 66.70
- Dipeptide instability weights (DIWV) · Guruprasad et al. 1990
- Above 40: classed as possibly unstable (ExPASy).
- Aliphatic index
- 0.0
- Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
- Boman index
- −1.64 kcal/mol
- Mean solubility value (negated) · Boman 2003
- 2.48 or below: lower protein-binding potential (Boman).
- Hydrophobic moment (μH)
- Not calculated
- The sequence is too short for this method.
- Not included: other modification. Mass, charge and pI are not calculated; use the identity-source values.
- The N-terminal group is not modeled.
- Defined and validated for proteins; use with care for short peptides.
- Assumes an ideal alpha helix. Many short peptides are not helical.
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
Net charge by pH
No charge curve
A modification changes this value and is not modeled here (for example a lipid, metal or linker).
Composition
- Aromatic50% (1)W
- Special50% (1)G
2 residues. Each residue counts in one class; F and W count as aromatic.
A Ala0 · 0%
I Ile0 · 0%
L Leu0 · 0%
M Met0 · 0%
V Val0 · 0%
F Phe0 · 0%
W Trp1 · 50%
Y Tyr0 · 0%
H His0 · 0%
K Lys0 · 0%
R Arg0 · 0%
D Asp0 · 0%
E Glu0 · 0%
N Asn0 · 0%
Q Gln0 · 0%
S Ser0 · 0%
T Thr0 · 0%
C Cys0 · 0%
G Gly1 · 50%
P Pro0 · 0%
3D structure
No 3D structure
No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.
2D structure
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 11281948(opens in a new tab)
C1=CC=C(C=C1)CCCCCC(=O)NCC(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)NResults by area
What the studies measured
People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
Trials and papers
Newer studies
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Status and safety
Data